Transforming growth factor beta 1 (TGF-b1) is a potent tumor suppressor but, paradoxically, TGF-b1 enhances tumor growth and metastasis in the late stages of cancer progression. This study investigated the role of TGF-b type I receptor, ALK5, and three mitogen-activated protein kinases (MAPKs) in metastasis by breast cancer cell line MDA-MB-231. We show that autocrine TGF-b signaling in MDA-MB-231 cells is required for tumor cell invasion and tumor angiogenesis. Expression of kinaseinactive ALK5 reduces tumor invasion and formation of new blood vessels within the tumor orthotopic xenografts in severe combined immunodeficiency (SCID) mice. In contrast, constitutively active ALK5-T204D enhances tumor invasion and angiogenesis by stimulating expression of matrix metalloproteinase MMP-9/gelatinase-B. Ablation of MMP-9 in ALK5-T204D cells by RNA interference (RNAi) reduces tumor invasion and tumor growth. Importantly, RNAi-MMP-9 reduces tumor neovasculature and increases tumor cell death. Induction of MMP-9 by TGF-b-ALK5 signaling requires MEK-ERK but not JNK, p38 MAPK or Smad4. Dominant-negative MEK blocks and constitutively active MEK1 enhances MMP-9 expression. However, all three MAPK cascades (ERK, JNK and p38 MAPK) are required for TGF-b-mediated cell migration. Collectively, our results show that TGF-b-ALK5-MAPK signaling in tumor cells promotes tumor angiogenesis and MMP-9 is an important component of this program.
Introduction
Metastasis is a complex process that involves tumor invasion, tumor vascularization and cell survival at distant sites (Hanahan and Weinberg, 2000) . Transforming growth factor beta (TGF-b)1 has been implicated in normal mammary gland biology and in breast tumorigenesis (Barcellos-Hoff and Ewan, 2000) . Although TGF-b1 is a potent tumor suppressor, metastatic breast cancer cells frequently express high levels of TGF-b1 that can promote cancer spreading via autocrine and paracrine mechanisms (Roberts and Wakefield, 2003) . The role of TGF-b1 in breast cancer metastasis has been extensively studied using transgenic mice and bone metastasis models (Siegel and Massague, 2003) , however, many mechanistic aspects of TGF-bmediated breast tumor invasion and metastasis originated from the orthotopic site remain incompletely understood. Given a dual function of TGF-b1 in cancer progression, it is important to determine specific components of the TGF-b pathway that contribute to tumor invasion and metastasis.
Members of the TGF-b family of cytokines signal through serine/threonine kinase transmembrane type I and type II receptors (Massague, 1998) . Binding TGF-b1 to the receptor complex triggers activation of type I receptor, also termed activin receptor-like kinase (ALK), which initiates downstream signaling involving Smad transcription factors, mitogen-activated protein kinases (MAPK), and PI3K-Akt signaling (reviewed by Derynck and Zhang (2003) ). TGF-b signaling is mediated by ALK5 and, in some cells, by ALK1 (Bertolino et al., 2005) . ALK5 phosphorylates Smad2 and Smad3, while ALK1 activates Smad1 and Smad5, triggering their translocation to the nucleus together with Smad4 (Massague, 1998) . In the breast cancer MDA-MB-231 cell line, TGF-b1 activates both Smad2/ 3 and Smad1/5 signaling suggesting that both ALK1 and ALK5 may operate in these cells . TGF-b-mediated activation of MAPKs may involve TGF-b-activated kinase 1 (TAK1) (Yamaguchi et al., 1995; Shibuya et al., 1996) or small GTPases (Hartsough and Mulder, 1995; Mucsi et al., 1996; Frey and Mulder, 1997; Adachi-Yamada et al., 1999; Engel et al., 1999; Bakin et al., 2002) . Activation of PI3K-Akt signaling by TGF-b receptors (Bakin et al., 2000; requires small Rho-like GTPases (Bakin et al., 2000) . MAPK and PI3K-Akt signaling cascades are activated independently of Smads signaling (Bhowmick et al., 2001b; . All three cascades have been implicated in EMT, cell migration and invasion, and potentially can contribute to the metastatic function of TGF-b1 (Roberts and Wakefield, 2003) .
Several studies have implicated p38 MAPK in TGFb-induced EMT in mammary epithelial cells (Bhowmick et al., 2001b; Bakin et al., 2002; Yu et al., 2002) and migration of human and mouse mammary carcinoma cells (Bakin et al., 2002) . In addition, TGF-b signaling contributes to invasiveness of breast carcinoma and melanoma cells by regulating matrix metalloproteinases (MMP) (Farina et al., 1998; Janji et al., 1999; Suarez-Cuervo et al., 2004) . Studies with kinase inhibitors have linked p38 MAPK to TGF-b-mediated regulation of matrix metalloproteinase-9 (MMP-9)/ gelatinase-B (Farina et al., 1998; Suarez-Cuervo et al., 2004) , urokinase plasminogen activator (uPA) (Huang et al., 2000) , MMP-1 and MMP-13 (Johansson et al., 2000) . However, a recent report from Cohen's group has shown that p38 MAPK inhibitors can effectively block the kinase function of TGF-b receptors (Eyers et al., 1998) , raising a question regarding the role of p38 MAPK in regulation of MMP-9 by TGF-b1. Although it is well documented that MMP-9 is required for tumor progression (Bergers et al., 2000; Welch et al., 2000) , the source of MMP-9 is still a subject of discussion. It has been shown that MMP-9 is secreted by tumor cells (Farina et al., 1998; Janji et al., 1999; Suarez-Cuervo et al., 2004) as well as by cells residing in stromal compartments (Chantrain et al., 2004; Jodele et al., 2005) .
The current study critically evaluates the proposed role of ALK5-MAPK signaling in regulation of MMP-9, the identity of MAP kinase that regulates MMP-9, and the role of tumor-produced MMP-9 in metastasis using the orthotopic xenograft model of breast cancer MDA-MB-231 cells in SCID mice. Experiments with kinase mutants of TGF-b type I receptor ALK5 reveal the important role of TGF-b-ALK5 signaling in tumor angiogenesis and metastasis. TGF-b-ALK5 signaling upregulates MMP-9 in tumor, but not MMP2/ gelatinase-A. The studies with dominant-negative (DN) kinase mutants of the p38 MAPK pathway and MAP kinase inhibitors show that MEK-ERK signaling, but not p38 MAPK and JNK, contributes to upregulation of MMP-9 in tumor cells. Ablation of MMP-9 in tumor cells by RNA interference (RNAi) reduces tumor growth and metastasis. Finally, tumor xenograft studies demonstrate that loss of MMP-9 abrogates TGF-b1-mediated tumor angiogenesis.
Results

TGF-b-ALK5 signaling activates MAP kinases in MDA-MB-231 cells
Human breast cancer MDA-MB-231 cells express TGFb type I and type II receptors and blockade of TGF-b signaling by a DN mutant of type II receptor inhibits formation of bone metastasis (Yin et al., 1999) . To investigate the mechanism by which TGF-b1 promotes tumor invasion and metastasis, the constitutively active TGF-b type I receptor ALK5-T204D and kinase-inactive ALK5-K232R were expressed in MDA-MB-231 cells using a bicistronic retroviral vector encoding EGFP (Bakin et al., 2002) . Expression of HA-tagged ALK5 mutants and their activity with respect to receptor-associated Smad2/3 (R-Smads), p38MAPK, and ERK signaling were characterized by immunoblotting (Figure 1a ). Kinase-active ALK5-T204D increased basal and TGF-b-induced levels of phosphorylation of Smad2/3, p38 MAPK, and ERK1/2 (Figure 1a) . In ALK5-T204D cells, Smad and MAPK signaling was enhanced by exogenous TGF-b1 indicating that formation of the receptor complex is required for maximum level of activation of these cascades. Importantly, kinase-inactive ALK5-K232R reduced TGF-b-mediated activation of R-Smads and MAP kinases and basal activation MAP kinases (Figure 1a ), indicating that these pathways are regulated by autocrine TGF-b-ALK5 signaling. The effect of ALK5 mutants on TGF-b transcriptional responses were measured using 3TP-Lux luciferase reporter that contains a fragment of PAI-1 promoter (Attisano et al., 1993) . Both Smad and MAPKs contribute to regulation of this promoter by TGF-b1 (Dennler et al., 1998) . In agreement with biochemical data, transcriptional activity of the 3TP-Lux reporter was affected by ALK5 mutants: the basal activity was increased by ALK5-T204D, whereas TGF-b-induced activity was reduced by ALK5-K232R (Figure 1b ). Together these findings show that TGF-b1 is capable of activating MAPKs and Smad2/3 in MDA-MB-231 cells and that constitutively active ALK5-T204D mimics TGF-b signaling to MAPK in these cells.
MAP kinases contribute to TGF-b-mediated enhancement of cell motility The effect of ALK5 mutants on cell motility was assessed in wound closure assays. The closure of wounds in control EGFP cells was stimulated by TGF-b1, whereas the wounds in the ALK5-T204D cells were closed even in the absence of TGF-b1 (Figure 1c) . The kinase-inactive ALK5-K232R mutant delayed the closure of wounds ( Figure 1c ). The cell growth was not affected by ALK5-K232R and ALK5-T204D within the timeframe of experiment (Figure 1d ), indicating that ALK5 stimulated cell motility but not cell proliferation. To determine the role of MAP kinases in TGF-bmediated cell motility, the ALK5-T204D cells were treated with inhibitors of MAPK signaling. Inhibitors of Raf and MEK (U0126), as well as inhibitors of JNK and p38MAPK blocked the closure of wounds (Figure 1e ). Similar results were obtained with EGFP cells in wound closure and transwell migration assays (data not shown). To confirm the role of p38 MAPK in TGF-bmediated cell motility, DN mutants of MKK6 (MKK6AL), an upstream MAPK kinase for JNK and p38 MAPK, and p38a (p38AF) (Raingeaud et al., 1996; Tibbles et al., 1996) were expressed in MDA-MB-231 cells. Both DN mutant kinases blocked wound closure in response to TGF-b1 (Figure 1f ). The expression of mutants was confirmed by immunoblotting (Figure 4a  and b ). These studies demonstrate that TGF-b-mediated tumor cell motility requires ALK5 and all three MAP kinases. Figure 1 Characterization of MDA-MB-231 cells overexpressing constitutively active T204D and kinase-inactive K232R mutants of ALK5, the TGF-b type I receptor. (a) Immunoblot analysis of whole-cell extracts from control EGFP and cells expressing HA-tagged ALK5 mutants. ALK5-T204D increases whereas ALK5-K232R reduces levels of phosphorylated forms of Smad2/3, p38 MAPK, HSP27 and ERK1/2. (b) Effect of ALK5 mutants on luciferase activity of 3TP-Lux reporter in MDA-MB-231 cells. Cells were treated with 2 ng/ml TGF-b1 for 16 h. Each data point represents the mean7s.d. of three wells. P-values were calculated using ANOVA test. Experiments were repeated at least two times. (c) TGF-b1 and active ALK5-T204D enhance whereas ALK5-K232R reduces closure of wounds in cell monolayers. Cells were treated with 2 ng/ml TGF-b1, where it is indicated. Phase contrast images were recorded at Â 100 magnification. Experiments were repeated at least three times. The effect of ALK5 mutants on tumor invasion was measured using Matrigel invasion assay. The ability of MDA-MB-231 cells to invade Matrigel was enhanced by TGF-b1 and kinase-inactive ALK5-K232R reduced both basal and TGF-b-induced invasion (Figure 2a) . Constitutively active ALK5-T204D markedly increased tumor cell invasion independent of TGF-b1 treatment. These data indicate that autocrine TGF-b-ALK5 signaling plays a critical role in invasive properties of MDA-MB-231 cells. Invasion of Matrigel by tumor cells was reduced nearly fourfold in the presence of GM6001, a general inhibitor of matrix metalloproteinases (MMPs) (Figure 2b) , showing an important role of MMPs in invasiveness of MDA-MB-231 cells. To measure the effect of ALK5 on MMPs, we performed substrate-gel zymography analysis of conditioned media. Parental and EGFP control MDA-MB-231 cells secreted pro-forms of both MMP-2/gelatinase-A (MW 72 kDa) and MMP-9/gelatinase-B (MW 92 kDa), but only MMP-9 was upregulated by treatment with TGF-b1 ( Figure 2c ). ALK5-T204D markedly increased levels of pro-MMP-9 without an effect on pro-MMP-2, whereas ALK5-K232R decreased basal and TGF-binduced MMP-9 (Figure 2c ). To determine whether ALK5 regulates mRNA levels of MMP-9, we performed RT-PCR analysis. TGF-b1 and ALK5-T204D significantly increased mRNA levels of MMP-9, whereas ALK5-K232R reduced induction of MMP-9 by TGF-b1 (Figure 2d ). Levels of MMP-2 transcripts were not regulated by TGF-b1 and ALK5-T204D (Figure 6a ). Collectively, these results indicate that TGF-b-ALK5 signaling upregulates expression of MMP-9/gelatinase-B thereby increasing the invasive properties of MDA-MB-231 cells.
The role of MAPKs in TGF-b-mediated regulation of MMP-9 To determine which MAP kinase is required for upregulation of MMP-9 by TGF-b-ALK5 signaling, ALK5-T204D cells were treated with MAP kinase inhibitors and the activity of secreted MMPs was measured by gelatin zymography. MEK and p38 MAPK inhibitors significantly reduced MMP-9 levels, whereas JNK inhibitor had no effect (Figure 3a) . Similar results were obtained with EGFP cells treated with TGF-b1 (data not shown). As a recent study has reported that p38 MAPK inhibitors can affect the kinase activity of TGF-b receptors (Eyers et al., 1998) , we compared the effect of p38 MAPK inhibitor on phosphorylation of Smad2/3, the ALK5 targets, and HSP27, a p38MAPK target (Beyaert et al., 1996) . The dose-dependence studies showed that p38 MAPK inhibitor effectively blocked phosphorylation of HSP27 starting at 1 mM (Figure 3b ). However, p38 MAPK inhibitor at concentrations 5 mM and above reduced phosphorylation of Smad2/3, suggesting inhibition of ALK5 (Figure 3b ). In contrast, JNK inhibitor did not affect phosphorylation of Smad2/3 but blocked phosphorylation of ATF2 (Figure 3c ). MEK inhibitor Cells were incubated in the presence of 1 ng/ml TGF-b1 where it is indicated. Invading cells were counted from five random fields in three wells. P-values were calculated using ANOVA test. Experiments were repeated at least two times. (b) Invasion of Matrigelcoated chambers by the EGFP cells in the absence (EGFP) or presence of 20 mM GM6001 (GM6001). Invading cells were counted from five random fields in three wells. Experiments were repeated twice. (c) Gelatinase activity in 48h-conditioned medium from control EGFP and ALK5 mutant cells. The band densities were evaluated using NIH-Image software. (d) RT-PCR analysis of b-actin (ACTB) and MMP-9 mRNA levels using total RNA samples from MDA-MB-231 cells expressing EGFP, ALK5-T204D and ALK5-K232R. Cells were un-treated/treated with 2 ng/ml TGF-b1 for 24 h. Fold differences represent the ratio of band densities for MMP-9 and ACTB. The band densities were evaluated using NIH-Image software.
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A Safina et al blocked phosphorylation of ERK1/2 ( Figure 3d ), but had no effect on Smad2/3 (data not shown). We also noted that phosphorylation of ERK1/2 was moderately reduced by 10 mM p38 MAPK inhibitor SB202190, but it was not affected by JNK inhibitor (Figure 3d ), indicating that p38 MAPK inhibitor non-specifically affects TGF-b receptors. The effect of kinase inhibitors on TGF-b transcriptional responses was determined using luciferase reporter SBE-Lux that scores Smad-dependent transcription. The analysis showed that Smadregulated transcription was reduced by two p38 kinase inhibitors in a concentration-dependent manner, whereas MEK inhibitor had no effect ( Figure 3e ). Together, these findings indicate that p38 MAPK inhibitors at high doses inhibit activity of TGF-b receptors. MEK inhibitor did not affect Smad-dependent transcription but blocked upregulation of MMP-9, suggesting that TGF-b1-mediated regulation of MMP-9 requires MEK-ERK signaling.
MEK signaling contributes TGF-b-mediated expression of MMP-9 As p38 MAPK kinase inhibitors showed a significant effect on Smad signaling, we examined whether p38 MAPK pathway affects TGF-b-mediated activation of Smads using kinase-inactive mutants of MKK6 (MKK6AL) and p38a MAPK (p38AF) (Raingeaud et al., 1996; Tibbles et al., 1996) . These mutants were expressed in MDA-MB-231 cells by retroviral infection using a bi-cistronic vector containing EGFP. DN MAPKs and MMP-9 in TGF-b-mediated metastasis A Safina et al MMK6AL (dn-MKK6) blocked activation of p38 MAPK and reduced phosphorylation of ERK1/2, without inhibition of Smad2/3 phosphorylation ( Figure 4a ). DN p38AF (Flag-tagged p38AF, dn-p38) did not affect phosphorylation of Smad2/3 but blocked phosphorylation of HSP27 ( Figure 4b ). Thus, both dn-MKK6 and dn-p38 block activation of p38 MAPK signaling but do not affect phosphorylation of Smad2/3. We next examined whether dn-p38 will not affect MMP-9 gelatinase activity. Gelatin zymography studies showed that dn-p38 indeed did not reduce MMP-9 expression ( Figure 4c ) indicating that p38 MAPK is not involved in upregulation of MMP-9 by TGF-b1. We also noted a moderate increase in MMP-9 activity by dn-p38 ( Figure 4c ). This effect could be associated with negative regulation of MEK-ERK signaling by p38 (Aguirre-Ghiso et al., 2003) . To test the role of MEK and Smad signaling in regulation of MMP-9, the ALK5-T204D cells were infected with adenoviruses encoding DN MEK1, constitutively active (ca) MEK1 or Smad4. Gelatin zymography studies showed that dnMEK1 reduced MMP-9 levels whereas caMEK1 increased MMP-9 ( Figure 4d ). Overexpression of Smad4 only marginally affected MMP-9. To complement this finding, Smad4 levels were modulated using siRNA. Transfection of siSmad4 effectively suppressed Smad4 in MDA-MB-231 cells but did not affect TGF-b-mediated regulation of MMP-9 ( Figure 4e ). These findings, together with the results of the MEK inhibitor study (Figure 3 ), indicate that MEK1 is required for upregulation of MMP-9 by TGF-b-ALK5 signaling.
Given that p38 MAPK has been implicated in regulation of urokinase-type plasminogen activator (uPA) in breast cancer cells (Huang et al., 2000; Suarez-Cuervo et al., 2004) , we examined mRNA levels of uPA by RT-PCR. The analysis showed that DN-mutants of MKK6 and MAPKs and MMP-9 in TGF-b-mediated metastasis A Safina et al p38a do not affect a basal and TGF-b-induced levels of uPA mRNA in MDA-MB-231 cells (Figure 4f ), indicating that this TGF-b response is independent of p38 MAPK signaling. Collectively, these studies demonstrate that upregulation of MMP-9 by TGF-b1 in MDA-MB-231 cells requires MEK-ERK, but not p38 MAPK or Smad4-mediated signaling.
TGF-b1 regulates ECM degradation by MMPs
Our studies showed that invasion of MDA-MB-231 cells was reduced by MMP inhibitor GM6001 and by kinaseinactive ALK5 (Figure 2 ). Although pro-MMP-9 was strongly induced by TGF-b-ALK5 signaling, the levels of active MMP-9 were not significantly increased (Figures 2-4) . Given that migration of MDA-MB-231 and other tumor cells in three-dimensional (3-D) matrix requires degradation of ECM by membrane-associated proteases (Friedl and Wolf, 2003) , we questioned whether TGF-b1 affects membrane-associated MMP activity. The ECM-degrading proteases are localized at cell-matrix focal contacts within invadopodia and podosomes, the cellular structures that promote cell invasion (Linder and Aepfelbacher, 2003; Seals et al., 2005) . The effect of TGF-b1 on these structures was assessed using the ECM-degrading assay in live cells (Seals et al., 2005) . Together, these studies show that TGF-b-ALK5 signaling stimulates MMP-dependent degradation of ECM at the cell-matrix focal contacts and that p38 is not required for this response.
MMP-9 contributes to TGF-b-mediated invasiveness but not motility of breast cancer cells To examine the role of tumor-derived MMP-9 in the metastatic potential of MDA-MB-231 cells, MMP-9 was stably suppressed by RNAi in control EGFP and ALK5-T204D cells using RNAi retroviruses encoding small hairpin RNA to MMP-9 (siMMP-9). RT-PCR analysis of puromycin-resistant cells revealed that siMMP-9 suppresses expression of MMP-9 in both EGFP and ALK5-T204D cells without off-target effects on MMP2 and PAI-1 (Figure 6a ). Gelatin zymography assays showed that siMMP-9 reduces levels of secreted MMP-9 in ALK5-T204D cells (Figure 6b) . Importantly, the ALK5-T204D-siMMP-9 cells and EGFP cells expressing siMMP9 showed a significant reduction in invasion of Matrigel (Figure 6c) . A less profound effect of siMMP9 on the invasion of the ALK5 cells than on the EGFP cells indicates that other factors downstream of ALK5 also contribute to migration and invasion of MAPKs and MMP-9 in TGF-b-mediated metastasis A Safina et al these cells. In contrast, the analysis of cell motility in wound closure assay revealed that siMMP-9 did not affect migration of cells on plastic (Figure 6d ). Taken together, these findings show that tumor-produced MMP-9 contributes to migration in 3-D matrix (invasiveness) of breast cancer cells.
Metastatic potential of MDA-MB-231 cells is affected by ALK5 mutants and siMMP-9
The metastatic potential of tumor cells expressing ALK5 mutants was examined by measuring colonization of lung surfaces by tumor cells after tail-vein injection (Tarin and Price, 1981) . Control EGFP and ALK5-T204D expressing cells were injected into the tail vein of SCID female mice, and 4 weeks later tumor colonies on lung surfaces were counted after staining with Indian ink. The ALK5-T204D cells formed nearly four times more colonies on lung surfaces compared to the EGFP cells (Figure 7a ), indicating that TGF-b signaling enhances the metastatic potential of MDA-MB-231 cells. The comparison of ALK5-T204D cells (T204D) and ALK5-T204D-siMMP9 (siMMP9) cells in the tail vein experiment showed a reduction of lung colonization by tumor cells expressing siMMP-9 to the levels of the EGFP cells (Figure 7a ). These findings suggest that MMP-9 is a critical component of the metastatic process mediated by TGF-b-ALK5 signaling.
TGF-b1 and MMP-9 alter tumor microenvironment by enhancing angiogenesis The effects of ALK5 mutants on tumor growth and the metastatic capacity were further investigated using the orthotopic xenograft model of spontaneous breast cancer metastasis (Price et al., 1990) . The control and ALK5 mutant cells were placed into the fat pads of 8-week-old SCID female mice. The ALK5-T204D xenografts grew at a significantly higher rate compared to EGFP control and ALK5-K232R (Figure 7b ). The analysis of cell proliferation, however, did not reveal significant differences in the Ki67 indices among all three tumor xenografts (Figure 7c ). The analysis of apoptotic cells using TUNEL staining of tumor sections showed roughly threefold high levels of the cell death in the EGFP and ALK5-K232R tumors compared to the ALK5-T204D tumors (Figure 7d ), indicating that active ALK5 enhances survival of tumor cells. The histological analysis showed the presence of metastases in lung but not to liver or spleen. The number of lung metastatic colonies was reduced in mice carrying the ALK5-K232R xenografts compared to control EGFP xenografts MAPKs and MMP-9 in TGF-b-mediated metastasis A Safina et al ( Figure 7e ). In contrast, the ALK5-T204D cells formed significantly more lung colonies than control cells (Figure 7e ). These results indicate that TGF-b1-ALK5 contributes to both the metastatic capacity of tumor cells and sustained tumor growth but does not affect cell proliferation. To determine the role of tumor-produced MMP-9 in TGF-b-mediated metastasis, we compared the growth and formation of metastasis by the ALK5-T204D (T204D) and ALK5-T204D-siMMP-9 (siMMP-9) cells. The growth of the siMMP-9 xenografts at the mammary fat pad was significantly delayed compared to T204D xenografts (Figure 8a ), although the proliferation Ki67 indices of both xenografts were similar (data not shown). These findings raised the question of whether siMMP-9 affected the survival of tumor cells. The analysis of TUNEL staining of tumor sections showed the presence of necrotic areas in the central part (core) of siMMP9 tumors as well as in control EGFP and ALK5-K232R tumors (Figure 8c ). In contrast, these areas were absent or significantly reduced in the ALK5-T204D tumors. The analysis of apoptotic cells outside of the necrotic areas at Â 400 magnification revealed a significant reduction of cell death in T204D tumors compare to siMMP-9 tumors (Figure 8c ), suggesting that MMP-9 is important for the survival function of ALK5-T204D. Given that sustained tumor growth requires angiogenesis (Folkman, 1971 ) and MMP-9 has been implicated in the angiogenic switch during tumorigenesis (Bergers et al., 2000) , we analysed angiogenesis within tumor xenografts by CD31 staining of endothelial cells. The analysis revealed the presence of CD31-positive (brown) endothelial cells and lumencontaining vessels (indicated by arrows) within the EGFP tumors (Figure 8c ). CD31 staining was significantly reduced in the K232R tumors, suggesting a reduction in the recruitment of vascular cells and formation of microvasculature. In contrast, the T204D tumors showed high levels of CD31 staining and extensive lumen-containing vessels, indicated by arrows (Figure 8c ). siMMP-9 significantly reduced the presence of lumen-containing vessels in tumor xenografts. The analysis of tumor sections for the highest number of discrete CD31-positive microvessels or 'microvessel hot spots' (Weidner et al., 1991) , showed that T204D tumors have higher levels of microvessel density compared to EGFP and K232R tumors (Figure 8e ). In T204D tumors expressing siMMP-9, the tumor microvessel density was reduced to the level of EGFP (Figure 8c and e). We hypothesized that the extensive vasculature found in T204D tumors may enhance tumor oxygenation. To test this possibility, we compared the oxygenation of tumors using hypoxyprobe assay (Bhattacharya et al., 2004) . The analysis showed the presence of extensive areas of hypoxia within the EGFP tumors compared to the T204D tumors (Figure 8f ), confirming the results of CD31 and TUNEL staining. Given that tumor angiogenesis may also be affected by inflammatory cells (Lewis and Pollard, 2006), we also analysed the presence MAPKs and MMP-9 in TGF-b-mediated metastasis A Safina et al of macrophages in tumors using F4/80 staining (Leenen et al., 1994) . The analysis showed the presence of macrophages in EGFP and K232R tumors but their reduction in the T204D tumors (data not shown). This finding is likely associated with reduced hypoxia and necrosis in the active ALK5 xenografts. Collectively, these findings suggest that TGF-b-ALK5 signaling in tumor cells contributes to recruitment of host vascular cells from stromal compartments and formation of blood vessels within the tumor, leading to reduced cell death and sustained tumor growth. MMP-9 is a critical component of this program. 
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Discussion
This study has investigated the mechanisms underlying the metastatic function of TGF-b1 in breast cancer MDA-MB-231 cells. We provide evidence that in breast carcinoma cells, TGF-b1 via type I receptor ALK5 activates MAP kinases to promote tumor angiogenesis and metastasis in the orthotopic xenograft model. ALK5 upregulates expression of matrix metalloproteinase MMP-9/gelatinase-B via a mechanism involving MEK-ERK, but not p38 MAPK, JNK or Smad4. Overexpression of dn-MEK1 and MEK inhibitor block upregulation of MMP-9 by ALK5. In contrast, dn-p38a and JNK inhibitor do not affect MMP-9. All three MAP kinases (ERK, JNK and p38) are required for cell migration, as kinase inhibitors reduce cell motility. Finally, suppression of MMP-9 in tumor cells by RNAi reduced tumor angiogenesis and tumor growth, as well as metastasis to lungs in the orthotopic xenograft model in SCID mice. RNAi to MMP-9 delayed tumor growth by reducing tumor neovasculature and increasing tumor cell death. TGF-b1 has been implicated in cancer progression by contributing to tumor invasion, suppression of immune response and alteration in tumor microenvironment (reviewed by Dumont and Arteaga (2000) , Roberts and Wakefield (2003) ). Previous studies have shown that disruption of TGF-b signaling in breast cancer MDA-MB-231 cells by overexpressing DN type II receptor (DN-TbRII) inhibits tumor cell motility and bone metastasis (Yin et al., 1999) . Here, we show that ALK5 mediates TGF-b1 signaling to enhance tumor cell motility and that all three MAP kinases (ERK, JNK, and p38 MAPK) contribute to this effect (Figure 1) . The p38 MAPK pathway may enhance cell motility by regulating actin remodeling factor HSP27 (Hedges et al., 1999) and by affecting actin polymerization and cell contractility (Huot et al., 1998; Hedges et al., 1999; Bakin et al., 2002) . MEK-ERK may regulate cell motility by preventing formation of extensive actin stress fibers via suppression of tropomyosin induction by TGF-b1 (Bakin et al., 2004) or inhibition of RhoA-Rho kinase pathway (Sahai et al., 2001; Pawlak and Helfman, 2002) . JNK may regulate motility by modulating the dynamics of microtubules (Huang et al., 2004) or by affecting the assembly/ stability of focal adhesion complexes via phosphorylation of paxillin and Spir, a WASP family protein (reviewed by Huang et al. (2004) ). The role of JNK in TGF-b-mediated cell motility, however, is less defined, given that inhibition of JNK does not affect TGF-bmediated actin remodeling and epithelial to mesenchymal transition (EMT) (Bhowmick et al., 2001a; Bakin et al., 2002 Bakin et al., , 2004 Edlund et al., 2002) .
Our results show that TGF-b-ALK5 signaling stimulates matrix invasion and up-regulates pro-MMP-9/ gelatinase-B, which is consistent with previous studies (Farina et al., 1998; Suarez-Cuervo et al., 2004) . A key and novel finding is that ALK5 stimulates MMP-9-dependent degradation of ECM at focal contacts, which is important for tumor cell migration in 3-D matrices such as collagen or Matrigel, that is invasion (Friedl and Wolf, 2003) . Consistent with this model, MMP inhibitor GM6001 or suppression of MMP-9 using RNAi reduced invasion of Matrigel and ECM degradation at focal contacts, but did not affect 2-D migration on plastic in wound closure assay (Figures 5 and 6 ). Another novel finding is that p38 MAPK is actually not required for upregulation of MMP-9 or uPA by TGF-b-ALK5 signaling. Several previous studies have used kinase inhibitors to implicate p38 MAPK in TGF-b-mediated regulation of MMP-9 (Farina et al., 1998; SuarezCuervo et al., 2004) , uPA (Huang et al., 2000) , and MMP-1 and MMP-13 (Johansson et al., 2000) . However, recent studies revealed that p38 MAPK inhibitors effectively block the kinase function of TGF-b receptors (Eyers et al., 1998) . We found that p38 MAPK inhibitors reduced MMP-9 expression only at concentrations that also affected TGF-b receptor activities way beyond the dose needed to inhibit p38 (Figure 3) . Moreover, overexpression of DN p38a in MDA-MB-231 cells blocked phosphorylation of HSP27 but did not affect regulation of MMP-9 and uPA (Figure 4 ). MMP-9 was not affected by inhibition of JNK (Figure 3 ). In contrast, MEK inhibitor reduced MMP-9 expression but did not affect Smad signaling (Figure 3) . In support of these findings, overexpression of dn-MEK1 decreased and ca-MEK1 increased MMP-9 levels, while Smad4 reduced MMP-9 (Figure 4) . Collectively, these results argue that TGF-b-ALK5 signaling upregulates MMP-9 via a mechanism involving MEK but not p38, JNK or Smads.
Animal studies with tail-vein and orthotopic xenograft models showed that the TGF-b-ALK5-MMP-9 pathway is an important factor in the metastatic phenotype of breast carcinoma cells (Figures 7 and 8) . Given that the tail-vein model tests the ability of tumor cells to invade lungs and to form non-angiogenic colonies on lung surfaces, the role of MMP-9 in this model is likely associated with its ability to degrade matrix of basement membrane and facilitate invasive migration of tumor cells. The orthotopic xenograft studies revealed angiogenic function of the ALK5-MMP-9 pathway. We found that xenografts of tumor cells expressing constitutively active ALK5-T204D (T204D) grew at higher rates than EGFP control or DN ALK5-K232R (K232R) xenografts. The immunohistochemistry (IHC) analysis showed a significant reduction of the cell death in the T204D xenografts compared to EGFP or K232R, whereas no difference in the proliferation Ki67 index was found (Figure 7) . Importantly, CD31 staining, a marker of endothelial cells (ECs), showed the presence of extensive neovasculature within the T204D tumors and a reduced hypoxia compared to the EGFP tumors, whereas the K232R tumors exhibited a significant reduction in CD31-positive cells (Figure 8 ). These findings indicate that the effects of TGF-b-ALK5 signaling support recruitment of vascular cells and/or maturation of tumor blood vessels, which is consistent with a critical role of the TGF-b pathway in vasculogenesis found in the studies with targeted disruption of TGF-b1 (Dickson et al., 1995) and TGF-b receptors, type II (Oshima et al., 1996) and type I (Larsson et al., 2001) . Suppression of MMP-9 resulted in the collapse of capillary-like vasculature within the T204D tumors and increased tumor cell death, but had little effect on the presence of ECs, suggesting that MMP-9 is likely involved in vessel maturation and to a lesser extent in the recruitment of ECs. These results are consistent with a current model that TGF-b-ALK5 signaling contributes to a maturation phase of vasculogenesis, whereas TGF-b-ALK1 signaling regulates migration and proliferation of ECs (reviewed by Jain (2003)). Given that kinase-inactive ALK5-K232R reduces CD31 staining, ALK5 may also regulate the recruitment of ECs to the tumor via a paracrine mechanism. In this regard, several studies have shown that MMP-9 is expressed at the sites of active angiogenesis and that MMP-9 is important for the mobilization of VEGF deposited in extracellular matrix (Bergers et al., 2000; Van den Steen et al., 2002) . Notably, the blockade of VEGF signaling reduces metastasis by MDA-MB-231 cells in the orthotopic xenograft model . In addition, it has been reported that TGF-b1 can regulate expression of VEGF (Benckert et al., 2003) . We found no significant difference in VEGF-A staining within tumor xenografts (data not shown), suggesting that TGF-b signaling does not affect VEGF levels in this model. Similar conclusions for MDA-MB-231 cells have been recently suggested (Suarez-Cuervo et al., 2004) . In addition to above-mentioned mechanisms, recent studies have suggested that MMP-9 may promote tumor angiogenesis by recruiting pericytes along vascular endothelial cells (Chantrain et al., 2004) , via a release of soluble c-kit ligand (Heissig et al., 2002) , and by recruiting bone marrow-derived precursor cells to the tumor stroma (Jodele et al., 2005) . Thus, multiple mechanisms may operate downstream of TGF-b-ALK5 signaling to enhance tumor angiogenesis and our results indicate that MMP-9 is a critical component of this program.
The main conclusions as well as the signaling cascades and reagents used in this study are summarized in Figure 9 . We show that the TGF-b-ALK5-MAPK-MMP-9 pathway is important for breast cancer invasion and angiogenesis. All three MAPK cascades (ERK, JNK and p38 MAPK) contribute to cell motility, whereas only MEK mediates upregulation of MMP-9, which plays a critical role in the tumor angiogenesis program regulated by TGF-b1. This study raises questions and provides the outline for the future studies. One important issue is that the interference with ALK5 or MEK-ERK signaling may disrupt tumor angiogenesis and reduce delivery of drugs to tumors, therefore, reducing the efficacy of therapeutic treatments. We propose that this problem can be solved with the use of nanoparticles or other reagents, which have higher rates of retention in tumors compared to conventional approaches. On the other hand, the enhancement of TGF-b-ALK5 signaling may improve tumor vasculature and enhance drug delivery. Other important issues are the mechanism by which TGF-b1 enhances the recruitment of host vascular cells to tumor and the specific function of MMP-9 during TGF-b-mediated angiogenesis. The link between MEK and MMP-9 expression also suggests that MEK inhibitors are potential agents for suppression of tumor angiogenesis and breast cancer progression.
Materials and methods
Antibodies, plasmids and other reagents TGF-b1 was obtained from R&D Systems (Minneapolis, MN, USA). The antibodies were obtained as follows Smad2/3 and rat antimouse CD31 from BD Biosciences, PharMingen, CA, USA; rabbit polyclonal to haemaglutinin (HA) epitope from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA); actin from Sigma; phospho-Smad2, phospho-p38 MAPK, phospho-ERK1/2, phospho-HSP27 and HSP27 from Cell Signaling Technology, MA, USA; Ki67 from Abcam, cat# ab833. Gelatin was from Sigma, cat# G9391; matrigel coated chambers were from BD Biosciences, cat #354480; and kinase inhibitors were from Calbiochem: U0126 for MEK; Raf kinase inhibitor I for Raf; SB202190 and p38 MAPK inhibitor III for p38 MAPK; and SP600125 for JNK. Retroviral constructs encoding HA-tagged MKK6-AL, Flag-tagged p38a-AF, HATagged ALK5 mutants, and EGFP are described in (Bakin et al., 2002) . Plasmids encoding puromycin-resistance gene and short interfering RNA (siRNA) targeting human MMP-9 (Acc#NM_004994) were purchased from Open Biosystems (Huntsville, AL, USA).
Cell culture
Human breast cancer MDA-MB-231 cells were obtained from American Tissue Culture Collection (ATCC) and cultured as recommended by ATCC. 
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Retroviral infection
MDA-MB-231 cells were infected in presence of 6 mg/ml of polybrene with amphotropic retroviruses produced in Phoenix cells as previously described (Bakin et al., 2002) . GFP-positive cells were selected by FACS. MDA-MB-231 cells expressing RNAi to MMP-9 were selected in the presence of 2 mg/ml puromycin.
Adenoviral infection of cells
Adenoviruses encoding EGFP, Flag-tagged Smad4, and constitutively-active (ca) MEK1-S218E,S222D and DN MEK1-S222A were produced using HEK-293T cells as described in (Bakin et al., 2004) . Smad4 adenovirus was provided by Kohei Miyazono, The Cancer Institute, Tokyo, Japan, and MEK1 adenoviruses were a gift of Andrey Sorokin, Medical College of Wisconsin, Milwaukee, WI, USA. Cells were incubated for 3 h with supernatant containing adenoviruses at 5-10 MOI. Medium was replenished and cells were grown for additional 24 h before further treatments.
Short interference RNA RNA duplexes against Smad4 were obtained from Dharmacon Inc. (Lafayette, CO, USA). A scramble control RNA duplex labeled with rhodamine was obtained from Qiagen (Chatsworth, CA, USA). Cells were transfected with RNA duplexes using Oligofectamine reagents (Invitrogen, Carlsbad, CA, USA) following the manufacturers protocol. The media was replenished next day. The cells were grown for additional 48 h in the absence or presence of 2 ng/ml TGF-b1 followed by gelatin zymography and immunoblotting.
Immunoblot analysis Cells were incubated in medium containing 5% serum for 24 h before treatment with 2 ng/ml TGF-b1. Kinase inhibitors were added 1 h before treatment with TGF-b1. Cells were lysed in buffer: 20 mM Tris, pH 7.4, 137 mM NaCl, 1% NP-40, 10% glycerol, 20 mM NaF, 1 mM Na orthovanadate, 1 mM PMSF, 2 mg/ml aprotinin and 2 mg/ml leupeptin. Immunoblot analyses of protein extracts were performed as described (Bakin et al., 2002) .
Transcription assay
The transcriptional assays were performed as described in (Bakin et al., 2004) using the following luciferase reporters: SBE-Lux (Dennler et al., 1998) containing 12 repeats of Smad binding sequence provided by J-M Gauthier, Laboratoire Glaxo Wellcome, Les Ulis Cedex, France; 3TP-Lux (Attisano et al., 1993) containing a fragment of PAI-1 promoter was a gift of J Massague, Memorial Sloan-Kettering Cancer Institute, New York, NY, USA; MMP-9-Lux containing a 670 bp fragment of the human MMP-9 promoter in pGL2 vector was obtained from J Bromberg, Memorial SloanKettering Cancer Institute, New York, NY, USA. MDA-MB-231 cells (3 Â 10 4 ) were seeded in 24-well plates. The cells were transfected with 0.16 mg/ml of a luciferase reporter and 0.002 mg/ml pCMV-Rl (Promega, Madison, WI, USA) using FuGENE6 reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's protocol. Cells were incubated for 8 h in 0.5% FBS-DMEM before treatment with 1 ng/ml TGF-b1 for 16 h. Firefly luciferase (Luc) and Renilla reniformis luciferase (Rl) activities in cell lysates were determined using the Dual Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol in a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA, USA). Luc activity was normalized to Renilla activity and presented as Relative Luciferase Units. All assays were carried out in triplicate wells and each experiment was repeated at least twice.
RT-PCR analysis RNA extraction was performed using Versagene RNA kit (Centra, Minneapolis, MN, USA). Amplification of transcripts was performed using 50 ng/ml of total RNA and one-step reverse transcriptase-polymerase chain reaction (RT-PCR) system from Invitrogen according to the manufacturing protocol. Primer sequences: b-actin (ACTB), Acc# NM_007393, forward: GCTGGTCGTCGACAACGGCTC, reverse: CAAACATGATCTGGGTCATCTTTTC; MMP-9, Acc#NM_004994, forward: TTCATCTTCCAAGGCCAATC, reverse CAGAAGCCCCACTTCTTGTC. PAI-1, Acc# NM_000602.1: forward TGCTGGTGAATGCCCTCTACT, reverse: CGGTCATTCCCAGGTTCTCTA MMP-2, Acc# NM_004530, forward: GGACTGCCCCCTGATGTCCA, reverse: AGGTCCACGACGGCATCCAG; MT-MMP1/MMP-14, Acc#NM_004995, forward: CATTGGAGGAGACACC CACT, reverse: TGGGGTTTTTGGGTTTATCA; UPA, Acc#NM_002658, forward: TGTGAGATCACTGGCTTTGG, reverse: AGGCCATTCTCTTCCTTGGT; UPAR, Acc#NM_ 002659, forward: TGTTGCAGCATTTCAGGAAG, reverse: AGCTATCGGACTGGCTTGAA.
Wound closure assay
The assay was performed as described previously (Bakin et al., 2002) . MDA-MB-231 cells (1-2 Â 10 5 /well) were seeded in 12-well plates and pre-incubated for 24 h in serum-free IMEM (Invitrogen) before wounding with plastic tip across the cell monolayer. The cells were left untreated or treated with 2 ng/ ml TGF-b1 for 16 h. The wound closure was estimated as the ratio of the remaining wounded area relative to the initial area. Experiments were repeated three times.
Proliferation assay
Proliferation of cells was evaluated using MTS assays according to manufacturer's protocol (Promega).
Matrigel invasion assay
Cells were mildly trypsinized and washed twice in IMEM with 0.1% BSA. Cells (1 Â 10 5 ) were seeded in the upper chamber coated with Matrigel (Calbiochem). The lower chamber was filled with 0.6 ml IMEM containing 0.1% BSA. TGFb-1 (1 ng/ ml) was added to the lower chamber. After 20 h of incubation, the non-migrating cells in the upper chamber were scraped away and cells present on the lower surface of the insert were stained with Diff-Quik Stain (Biochemical Sciences Inc., Swedesboro, NJ, USA). Invading cells were counted from five random fields in three wells. Experiments were repeated at least twice.
Gelatin zymography
Conditioned media of cells incubated in serum-free IMEM for 48 h was removed and centrifuged. Sodium dodecyl sulfateployacrylamide gel electrophoresis (SDS-PAGE) gels were copolymerized with gelatin at a final concentration of 1 mg/ml. After electrophoresis, the gels were renaturated in 2.5% Triton X-100 and incubated at 371C for 24 h in 5 mM CaCl 2 and 50 mM Tris-HCl buffer, pH 7.5, containing 0.05% NaN 3 . The gels were stained with 0.5% Coomassie Blue R-250 and destained in 10% methanol and 5% acetic acid in water. Gelatinolytic activities were detected as transparent bands on the blue background. The band densities were evaluated using NIH-Image software.
Animal studies using a tail-vein injection model Female SCID/CB17 mice, 8 weeks of age, were obtained from a colony of SCID/CB17 mice that was bred and maintained at the Department of Laboratory Animal Resources (DLAR) facility at the Roswell Park Cancer Institute (RPCI). All animals were kept three to five mice per cage in microisolator units and provided with water and food ad libitum according to a protocol approved by the Institute Animal Care and Use Committee at RPCI. The facility has been certified by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulation and standards of the US Department of Agriculture and the US Department of Health and Human Services.
Exponentially growing breast cancer cells (2.5 Â 10 6 ) in 0.2 ml of sterile Hank's solution were injected using 28-G needle into a tail-vein of 8-week-old female SCID/CB17 mice. Mice were killed 4 weeks thereafter. Lungs were stained with Indian black ink and tumor colonies on lung surfaces were counted as described in (Wexler, 1966) .
Animal studies using an orthotopic xenograft model Exponentially growing tumor cells (1 Â 10 6 ) in 0.1 ml Hank's buffered salt solution were inoculated into the surgically exposed mammary fat pad (m.f.p.) of 7-to 8-week-old female SCID mice. The growth of primary tumors was monitored by measuring tumor diameters with electronic calipers every 3-4 days continuously from the third week after injection. Volumes were calculated using the formula (length) Â (width) 2 /2. Primary tumors were removed at 1 cm diameter, typically 30-35 days after appearance of palpable tumors. After 4-5 weeks, the mice were killed, lungs, bones, spleens, livers were collected, and histological analysis was performed at the RPCI Pathology Core Facility.
Immunohistochemistry
Tumor specimens were fixed immediately in 10% (v/v) formalin and then embedded in paraffin. For CD31 staining, harvested tumors were fixed in Zink fixative (BD Biosciences). Before immunostaining, conventional H&E-stained sections were prepared for general histopathologic evaluation. For Ki-67 staining, formalin-fixed tissue sections were incubated for 1 h at room temperature with the rabbit polyclonal primary antibodies to human Ki-67. Biotinylated secondary goat antirabbit antibodies were applied for 30 min followed by 30 min incubation with the ABC reagent (Vector Labs). Ki-67 labeling index was calculated as the percentage of positive tumor nuclei divided by the total number of tumor cells examined. At least 1000 tumor cells per specimen were examined in five random fields using light microscopy at 400-fold magnification. For CD31 staining harvested tumors were fixed in Zink fixative (BD Biosciences) overnight and then processed for paraffin sections. The rat anti-mouse primary antibody to CD31 (BD Biosciences) was applied for 1 h at room temperature followed by 30 min incubations with biotinylated secondary anti-rat antibody (BD Biosciences) and the streptavidin complex (Zymed Lab Inc., San Francisco, CA, USA). The analysis of microvessel density was performed as described in (Weidner et al., 1991) . Briefly, tumor sections were scanned at Â 100 magnification for the areas containing the highest number of discrete CD31-positive microvessels ('microvessel hot spots'). Necrotic and immediately adjacent areas where microvessels are sparse were excluded from counting. CD31-positive (brown stain) vessels were counted at Â 400 magnification in eight fields of each tumor section. The results were presented as mean number of microvessels/field (0.2 mm 3 ) 7s.d.
Apoptosis assay
TUNEL staining was used for in situ detection of apoptotic cells in paraffin sections of tumor tissues using the ApopTag in situ detection kit (ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit, Chemicon, cat #S7101) following the manufacturer's recommendations. Cells were examined in five random fields using light microscopy at 400-fold magnification.
Hypoxyprobe Hypoxyprobe (pimonidazole hydrochloride, NPI, Belmont, MA, USA) at 60 mg/kg was injected 2 h before killing intraperitoneally into SCID mice carrying MDA-MB-231 m.f.p. xenografts as described in (Bhattacharya et al., 2004) . Formalin-fixed tissue sections were incubated with the primary antibody Hypoxyprobe-monoclonal antibody (1.4 mg/ ml, NPI, Belmont, MA, USA) for 1 h at room temperature. Incubation with biotinylated IgG fragment (F(ab 0 )2, Accurate Chemical&Scientific Corporation, Westbury, NY, USA) for 10 min was followed by 30 min incubation with the streptavidin complex (Zymed Lab Inc.).
Statistical analysis
Continuous data were compared using the Student's t test. Differences were considered significant when Po0.05.
Abbreviations
MAPK, mitogen-activated protein kinase; MMP-9, matrix metalloproteinase-9; TGF-b, transforming growth factor beta.
